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simulated errors had gamma values greater than 1, and fail 
the criteria. In addition to dwell positions and times analysis, 
the system was capable of determining the transit time 
between dwell positions and its effect on the estimated dose 
delivered when compared against the treatment plan. 
 
Figure 1 - The position-time gamma analysis of the modified 
plan. 
Conclusions: Our application of the developed quality 
assurance system 'magic phantom', to HDR brachytherapy has 
demonstrated ability to perform the verification of all HDR 
treatment plans. This device has shown potential to be the 
comprehensive QA solution for the entire treatment delivery, 
with further development of this system focused on real time 
in vivo source tracking.  
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Purpose/Objective: One of the important proceedings of 
brachytherapy during the last years was the clinical 
implementation of modern planning algorithms. To provide 
guidelines to the medical physicist the AAPM TG-186 
published a report that describes procedures for 
commissioning new treatment planning algorithms (TPSs) in 
brachytherapy. To evaluate the guidance of this report from 
the end-users perspective we describe in this work the 
commissioning process of a commercial model-based dose 
calculation algorithm (MBDCA) for an HDR afterloading device 
in our clinic according to TG-186. We furthermore study 
complemental dose measurements. 
Materials and Methods:The TPS BrachyVision v11.0.47 
utilizing the dose calculation algorithm Acuros v1.5.0 for an 
Ir-192 HDR GammaMedplus afterloader (Varian Medical 
System, Palo Alto, CA) was used for this study. In the first 
step the commissioning process, as recommended by the TG-
186 report, was followed for level 1. Dose comparisons 
between TG-43 formalism and Acuros were carried out in 
water medium for a single source scenario of 40700 U. 
Moreover hand calculations were performed for several 
points of interest using along away table for the relevant TG-
43 consensus data. 
Measurements in a water tank (40x40x40 cm3) using a 
Semiflex chamber, type 31010, (PTW Freiburg, Germany) 
were conducted. Dose measurements are in particular of 
interest to validate the impact of heterogeneities in the 
Acuros module. They were carried out at various points of 
interest, laterally and distally positioned from the source. 
Therefor the source was either positioned in an implant 
needle made of steel or in a shielded 90° vaginal cylinder of 
3.5 cm diameter. This shielded cylinder is also virtually 
available for dose calculation as template in the applicator 
library of the BrachyVision/Acuros system. 
Results: Results of computations and measurements in water 
are summarized in Table 1. Hand and TG-43 based 
calculations are close to results of the Acuros computations 
(better than 2% for all points). As expected, dose 
measurements close to the source show deviations (about 
30% at 1,14 cm), but reached reasonable accuracy at longer 
distances (e.g. 5% at 7,11 cm). 
Dose values behind the shielding of the vaginal applicator are 
shown in Figure 1. Good agreement was reached between 
measurements and the results of the MBDCA. TG-43 
formalism takes heterogeneities not in to account, so the 
computed doses are not accurate behind the shielding. 
 
 
Conclusions: Commissioning of a MBDCA is well feasible when 
following the TG-186 report, level 1. In addition dose 
measurements in water can complete the procedure to check 
the impact of heterogeneities in the medium. 
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Purpose/Objective: Dose surface maps (DSM) provide spatial 
features of the rectal wall dose distribution which has been 
shown to correlate with tissue toxicity in different ways 
(Buettner et al 2009). This study aims to develop the 
methodology and assess feasibility of using DSM to 
accumulate rectal wall dose from both external beam 
radiotherapy (EBRT) and brachytherapy (BT) in cervical 
cancer patients. This was previously not possible using 
conventional dose volume histogram due to lack of spatial 
information and challenges with anatomical difference 
between the two therapeutic modalities. 
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Materials and Methods: 20 cervical cancer patients who 
underwent treatment at Royal Marsden Hospital were 
identified retrospectively. Both EBRT and BT plans were 
retrieved from radiotherapy archive. The plans were 
anonymised and transferred to VODCA-RT (MSS 
GmbH,Hagendorn,CH) which is a dosimetric analysis 
software. The rectum was recontoured using standardised 
anatomical definition of 2.5cm from anal canal to the 
rectosigmoid junction. Posteriorly cut DSM were generated 
using VODCA-RT for both EBRT and BT. The raw data was 
then organised using in-house R script before being 
normalised to 21x21 pixels using MATLAB (Mathworks, Natick, 
MA). Assuming an α/β ratio of the linear quadratic model of 
3Gy for the rectum, equivalent BED dose in 2Gy conversion 
was made using the equation shown below.  
 
Dose values of corresponding pixels were then summated to 
derive the respective DSM. Maximum rectal toxicity such as 
bleeding and proctitis within 6 months of treatment were 
also recorded using CTCAE v4.0. Statistical analysis was 
performed using MedCalc software v14.10.2. 
Results: Combined rectal DSM were successfully generated 
for all 20 patients using our methodology. An example of a 
combined DSM is illustrated in figure 1. As expected, there 
was significant variation between the mean rectal volume 
during EBRT and BT (67.71cc and 53.99cc respectively, 
p=0.0189) due to presence of brachytherapy applicator and 
rectal retractor. There was also a mean difference of 0.59cm 
between EBRT and BT rectal cranio-caudal length (p=0.049). 
This is most likely to be due to true anatomical variation 
between both time points e.g. angulation of upper rectum. 
Normalisation to 21x21 pixels was therefore felt to be a good 
compromise to account for these anatomical differences 
whilst maintaining relatively accurate spatial dose 
distribution following dose summation. Consistent with 
previously published study by Buettner et al, ROC analysis on 
our data also demonstrated that lateral extent (rectal 
circumference) receiving >60Gy is a good predictor of risk of 
G1-3 proctitis (AUC=0.879,p<0.0001). 
 
 
Conclusions: Rectal dose summation using DSM for cervical 
EBRT and BT is feasible. This method retains valuable spatial 
information which is closely correlated to toxicity. We 
propose a follow-up study with a bigger cohort incorporating 
organ motion for further validation of DSM as alternative 
eassessment of rectal constraints in cervical cancer patients. 
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Purpose/Objective: Radical radiation therapy comprising of 
external beam radiotherapy(EBRT) and intracavitary 
brachytherapy with concurrent chemotherapy,is the gold 
standard for management of locally advanced cervical 
cancers. Brachytherapy forms the mainstay of treatment for 
local control rates and toxicities.Recent reports indicate that 
image-guided BT (IGBT) improves local control and late 
morbidity. MR imaging is the gold standard for IGBT practice 
which have been well described in GEC-ESTRO I-IV 
recommendations.However, various survey reports suggest 
the limited availability of MR and logistics with radiology 
units.On the other hand,CT Imaging is available in the 
radiotherapy units. There has been an increased interest in 
the use of CT during IGBT in Cervical Cancers. With an aim to 
validate CT based IGBT in terms of OAR and HR-CTV 
contouring we undertook this sub-study as a part of ongoing 
prospective EMBRACE study.  
Materials and Methods: Patients who were recruited for the 
EMBRACE study ,after completion of EBRT,underwent BT 
application with MR/CT compatible applicators. A planning 
CT with I.V contrast and appropriate bladder filling protocol 
followed by T2w-MR Imaging for BT planning was performed. 
HR-CTV and OAR's were contoured on CT images based on 
pre-Rx MR, clinical findings at diagnosis and at BT.First the 
contouring was done on CT images followed by on T2w-MR 
Images.HR-CTV and OAR volumes and HR-CTV dimensions 
(height, width and thickness) were analyzed and compared.  
Results: So far, 27 patients (Mean Age:47±8.4 years) with 
histologically proven cervical cancer,with FIGO (2009) Stage 
IB to IIIB (IB2-1,IIB-13, IIIB-12, IVA-1) who underwent CT and 
MR during IGBT process were analyzed.The mean + SD 
volumes of rectum, bladder and sigmoid on CT was 40 ± 20.0 
cc, 79 ± 30.6 cc and 40.4 ± 26.7 cc as compared to 33 ± 11.6 
cc, 84.7 ± 29.6 cc, 35.6 ± 19.7 cc on MR respectively.The 
mean + SD HR-CTV on CT was 41.3 ± 23.6 cc while it was 42 ± 
23.6 cc on MRI with a Pearson's correlation co-efficient of 
0.921 (p<0.001).The mean + SD maximum height, width and 
thickness on CT was 44.4 ± 10.5mm, 47.6 ± 6mm and 33.5 ± 
5.3mm while it was 44.8 ± 10.5mm, 46 ± 7.2mm and 34.8 ± 
7.5mm on MR. The correlation coefficients were 0.73 (p = 
0.00) for height,0.61 (p<0.00) for width and 0.76 (p<0.00) for 
thickness.Since the correlation for width was least, we 
divided the patients into 3 groups:no parametrial 
invasion,medial parametrial invasion and lateral parametrial 
invasion at the time of BT. The correlation coefficient were 
0.76 (p <0.00), 0.77 (p <0.00) and 0.54 ( p <0.53 ) for the 
three groups respectively. To estimate the differences 
further,the mean+ SD difference between CT and MR for 
various dimensions were as follows: 0.37 ± 7.6mm for height, 
-1.5 ± 4.8 mm for width and 1.3 ±5.9 mm or thickness 
respectively.  
Conclusions: As compared to MR Based contouring,the OAR 
and HR-CTV volumes are comparable.On evaluation of HRCTV 
maximum dimensions,the correlation was highest for 
